Biovest to Present at World Vaccine Congress 2010
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Apr 20, 2010 - Biovest International, Inc. (Other OTC:BVTI) today announced that the Company will be making a presentation regarding its personalized cancer vaccine, BiovaxID®, on April 22 at the World Vaccine Congress which is currently ongoing in Washington D.C.
Biovest's Vice President, Product Development & Regulatory Affairs, Dr. Carlos Santos, will deliver a presentation titled, “Personalized biologic therapeutic cancer vaccine for the treatment of non-Hodgkin's lymphoma” as part of the Cancer Immunotherapies track of the conference. Other companies presenting as part of the Cancer Immunotherapies track include Dendreon, BioVex, GlaxoSmithKline and Vaccinogen.
Event: World Vaccine Congress 2010
Place: Westfields Marriott Washington Dulles
Biovest Presentation Day/Time: Thursday, April 22nd at 11:15 a.m.
If conference attendees are interested in scheduling a one-on-one meeting with Dr. Santos at this event, please contact Douglas Calder at 813-864-2558 or email@example.com.
About Biovest International, Inc.
Biovest International, Inc. is an emerging leader in the field of personalized immunotherapies targeting life-threatening cancers of the blood system. Developed in collaboration with the National Cancer Institute, BiovaxID® is a patient-specific, anti-lymphoma cancer vaccine, demonstrating statistically significant Phase III clinical benefit by prolonging disease-free survival in patients suffering from indolent follicular non-Hodgkin's lymphoma. BiovaxID has been granted Orphan Drug Designation by both the U.S. FDA and the European EMEA. Biovest has also developed and markets a proprietary line of automated hollow fiber bioreactor systems, including the innovative AutovaxID™ which is a production platform for the scalable manufacture of difficult-to-produce biologics including personalized medicines, monoclonal antibodies, cell culture vaccines and therapeutics targeting highly infectious agents. Since 1981, Biovest has been offering its clients a wide range of instrumentation and cell culture contract manufacturing services. Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the Over-the-Counter (OTC) market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ).
For further information, please visit: http://www.biovest.com
Forward-Looking Statements: Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to statements about BiovaxID®, AutovaxID™, events occurring after dates hereof, and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Douglas Calder, Director of Investor Relations & Public Relations
Posted: April 2010